Trial
NCT04522375
A Dose Escalation Study of FP-045 in Patients With Fanconi Anemia
Phase IWITHDRAWNSAFETYConfidence: MEDIUM
Sponsor
Foresee Pharmaceuticals Co., Ltd.
Collaborators
—
Condition
Fanconi Anemia
Intervention
FP-045
Why stopped
Twenty months after investigative site initiations, and best efforts to identify study participants, no participants were identified.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-03-06